Will Japan s Canon Be the Next Giant to Take its Shot at the Microarray Arena? | GenomeWeb

In a move championed by Fujio Mitarai, the 65-year-old president and CEO of Canon, the Tokyo-based digital technology giant will increase spending on research and development by 2 percent annually within the next two years, with some of those funds, according to news reports, heading to commercializing DNA microarray production based on the company's pioneering ink-jet technology.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.